Centella asiatica: what asiaticoside and madecassoside do for skin

Centella asiatica has a long record in wound care and dermatology, and unusually for a traditional botanical, the modern literature has narrowed the activity down to identifiable molecules rather than leaving it at extract level. The two that carry most of the skin evidence are asiaticoside and madecassoside — pentacyclic triterpene saponins that occur in the aerial parts of the plant alongside their aglycones, asiatic acid and madecassic acid. The reviews by Bylka et al. in Postepy Dermatologii i Alergologii and Phytotherapy Research both treat this triterpene fraction, not the whole herb, as the active principle in cosmetic and dermatological use.

Mechanism, as far as the fibroblast work supports it. The collagen research is the most consistent part of the record: asiaticoside and madecassoside are associated with increased synthesis of type I and type III collagen in human dermal fibroblasts. That distinction matters for skin. Type I collagen is the dominant structural protein of mature dermis; type III is the more elastic form laid down early in repair and present in higher proportion in younger skin. An input that raises both, rather than only one, is doing something closer to remodelling the matrix than simply thickening it — which is why the same molecules recur in both anti-aging and post-procedure repair briefs rather than only in one of them.

Wound healing and scar management is where the clinical use is oldest. Titrated extract of Centella asiatica — TECA, a standardised preparation defined by fixed proportions of asiaticoside, asiatic acid and madecassic acid — has been studied in wound healing and scar contexts, and its very existence makes the point of this article: the pharmacological literature does not study "Centella extract," it studies a preparation with a declared triterpene composition. When a formulator cites that literature for a finished product, the citation is only as good as the compositional match between what was studied and what is in the drum.

Which is where sourcing diverges sharply from the marketing category. "Centella extract" as a purchasing term is close to meaningless on its own: it can describe a low-percentage aqueous extract, a ratio extract with no stated triterpene assay, or a preparation standardised to a defined asiaticoside and madecassoside content. All three ship under the same INCI name. The literature above applies to the third; nothing about being derived from the same plant makes the first two behave the same way in a formulation.

Reading a Centella specification. Four names circulate on supplier documents and they are not interchangeable. Asiaticoside and madecassoside are the glycosides — the sugar-bearing forms that dominate the fibroblast and collagen literature. Asiatic acid and madecassic acid are their corresponding aglycones, the same triterpene skeletons without the sugar. TECA is defined by a fixed combination of one glycoside with two acids, which is precisely why a specification quoting only a total-triterpene figure, or only asiaticoside, is not directly comparable to the TECA clinical record even though every one of those molecules is genuinely from Centella. Matching a citation to a raw material means matching the named compounds and their proportions, not the plant name.

The practical questions for a supplier are narrow and answerable. Which triterpenes are assayed, and at what declared percentages. By what analytical method — an HPLC assay with a named reference standard, or a spectrophotometric total-saponin figure that cannot distinguish asiaticoside from anything else in the same class. How tightly those numbers hold from batch to batch, since a claim built on a single flattering certificate of analysis fails the moment the second lot arrives. And whether the plant material's origin and harvest stage are controlled, since triterpene content in Centella varies with both.

None of this makes the extract choice complicated — it makes it explicit. A standardised, assayed Centella fraction lets a formulator connect a finished product to the published fibroblast and wound-healing work with a defensible line of reasoning. An unstandardised one may perform identically, but nothing on its paperwork lets anyone say so, and in a category where the evidence sits at the molecule level, that gap is the difference between a supported claim and a botanical association.